Unexpected drug-drug interactions in human immunodeficiency virus (HIV) therapy: Induction of ugt1a1 and bile efflux transporters by efavirenz

Annals of the Academy of Medicine Singapore

Volumn 41, Issue 12, 2012, Pages 559-562

  Lee, Lawrence Su ^a,b   Pham, Paul ^c   Flexner, Charles ^c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug transporters; Drug drug interactions; Efavirenz; HIV therapy; UGt1A1

Indexed keywords

BILIRUBIN; BILIRUBIN GLUCURONIDE; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; GLUCURONOSYLTRANSFERASE 1A1;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG DRUG INTERACTION; FEMALE; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACULOPAPULAR RASH; MALE; NORMAL HUMAN; OPEN STUDY; PHARMACODYNAMICS; SPECTROPHOTOMETRY;

EID: 84872175723     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Lee LS, AndraDe AS, Flexner C. Interactions between natural health products and antiretroviral drugs: pharmacokinetic and pharmacodynamic effects. Clin Infect Dis 2006;43:1052-59.
2. Pham PA, Flexner C. Emerging antiretroviral drug interactions. J Antimicrob Chemother 2011;66:235-9.
3. Maggiolo F. Efavirenz: a decaDe of clinical experience in the treatment of HIV. J Antimicrob Chemother 2009;64:910-28.
4. Bristol-Myers Squibb Company. Sustiva (efavirenz) tablets. FDA approved label, 2011.
5. Lee LS, Panchalingam A, Yap MC, Paton NI. Pharmacokinetics of indinavir at 800, 600, and 400 milligrams administered with ritonavir at 100 milligrams and efavirenz in ethnic chinese patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 2004;48:4476-8.
6. Soon GH, Shen P, Yong EL, Pham P, Flexner C, Lee L. Pharmacokinetics of darunavir at 900 milligrams and ritonavir at 100 milligrams once daily when coadministered with efavirenz at 600 milligrams once daily in healthy volunteers. Antimicrob Agents Chemother 2010;54:2775-80.
7. Iwamoto M, Wenning LA, Petry AS, Laethem M, De Smet M, Kost JT et al. Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother 2008;52:4338-43.
8. Wang LZ, Lee LS, Thuya WL, Soon GH, Kong LR, Nye PL, et al. Simultaneous determination of raltegravir and raltegravir glucuroniDe in human plasma by liquid chromatography-tandem mass spectrometric method. J Mass Spectrom 2011;46:202-8.
9. Lee LS, Wise SD, Chan C, Parsons TL, Flexner C, Lietman PS. Possible differential induction of phase 2 enzyme and antioxidant pathways by american ginseng, Panax quinquefolius. J Clin Pharmacol 2008;48:599-609.
10. Lee LS, Stephenson KK, Fahey JW, Parsons TL, Lietman PS, AndraDe AS, et al. Induction of chemoprotective phase 2 enzymes by ginseng and its components. Planta Med 2009;75:1129-33.
11. Pham PA, la Porte CJ, Lee LS, Van Heeswijk R, Sabo JP, Elgadi MM, et al. Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers. Antimicrob Agents Chemother 2009;53:4385-92.
12. Jemnitz K, Veres Z, Tugyi R, Vereczkey L. Biliary efflux transporters involved in the clearance of rosuvastatin in sandwich culture of primary rat hepatocytes. Toxicol In Vitro 2010;24:605-10.
13. Vlaming ML, Van Esch A, Van De Steeg E, Pala Z, Wagenaar E, Van Tellingen O, et al. Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate. Drug Metab Dispos 2011;39:1338-44.
14. Haenisch S, May K, Wegner D, Caliebe A, Cascorbi I, Siegmund W. Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol. Pharmacogenet Genomics 2008;18:357-65.
15. Faucette SR, Zhang TC, Moore R, Sueyoshi T, Omiecinski CJ, LeCluyse EL, et al. Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther 2007;320:72-80.
16. Lee LS, Soon GH, Shen P, Yong EL, Flexner C, Pham P. Darunavir/ritonavir and efavirenz exert differential effects on MRP1 transporter expression and function in healthy volunteers. Antivir Ther 2010;15:275-9.